About us

Developing a new class of drugs for millions of patients suffering from cardio-renal pathologies with no therapeutic solution

V4Cure is based on CEA research into the use of animal toxins as a source of therapeutic molecules. The start-up is focusing its efforts on one of them, V4C-232, with two indications in cardio-renal diseases.

V4C-232 is a first-in-class synthetic molecule derived from a pepitde found in the venom of the green mamba, a sub-Saharan African snake. The potency and safety of V4C-232 in treating volume overload conditions
and rare polycystic kidney disease was demonstrated in preclinical studies.

V4Cure is developing V4C-232 as a new drug candidate to treat refractory ascites (unresponding to diuretics) in liver cirrhosis, as the primary indication. This is a critical condition with an unmet medical need, as there is currently no effective drug therapy available. Refractory ascites occur in 10% of patients developing ascites and affect the survival rate. V4C-232 represents a safe and effective solution for these patients.

V4Cure is conducting pharmacological studies and drug candidate developments, to then launch phase 1 and 2 clinical studies. Meanwhile, V4Cure is also developing another V4C-232-based product as a new therapy for polycystic kidney diseases (ADPKD and ARPKD). These rare, chronic, genetic, and progressive diseases could lead to severe renal failure, with very limited therapeutic options, especially for Children.

References

Refractory ascites in liver cirrhosis affect ~10 millions of patients worldwide
Prevalence of ARPKD is estimated to be annualized prevalence is 1.17 per 100,000 (1 in 20:000 births)

Our Team

A seasoned team of healthcare professionals with complementary expertise

Dr. Sonia Escaich

CEO

PhD in human biology
25 years in pharma R&D, 20 years in biotech management and creation

Dr. Thierry Verrecchia

CTO

PharmD, PhD in immunochemistry
20 years in pharma industry
10 years on the equity market

Dr. Nicolas Gilles

Scientific advisor

PhD in biochemical pharmacology
20 years in research at CEA
5 patents and 76 publications

Henry Dorbes

CFO

MBA, expertise in international finance for large and small healthcare companies

Our Board of Directors

Dr. Pascale Richetta, MD

Board member

30-years in Pharma & Biotech industry
9-years on Pharma & Care Boards

Nabil Gharios

Board member

Centrale Engineer, Former Abbott executive, 20-years in M&A, Life Science investments

Thomas-Paul Descamps

Board member

MBA, 30-years in Pharma & Biotech industry
Jellagen CEO, Biotechs Board member

Lionel Delaporte

Board member

25-years in Health Care and Lite Sciences strategic consulting. Managing Partner at AEC Partners.

Science

Science

Pipeline

Pipeline

Partners

V4Cure is a spin-off of CEA.

V4Cure received the national ILAB grant
for innovation with the Honor Award in 2022.

V4Cure is a member of Paris Biotech Santé Biotech incubator.

News

Coming soon.

Information

Contact us